As of 2024, glucagon-like peptide-1 receptor agonists (GLP-1RAs) rank among the top-selling drugs globally and are gaining recognition as potential therapeutic agents for alcohol use disorder (AUD), with growing interest in their roles in modulating alcohol consumption and alcohol craving (Table 1). Here, GLP1R is linked to alcohol abuse.